As Valeant Pharmaceuticals Intl (Put) (VRX) Shares Declined, Soros Fund Management LLC Decreased Stake by $13.20 Million

April 14, 2018 - By Lisa Delgado

Valeant Pharmaceuticals International, Inc. (NYSE:VRX) Corporate LogoDuring Q4 2017 the big money sentiment decreased to 0.97. That’s change of 0.02, from 2017Q3’s 0.99. 51 investors sold all, 74 reduced holdings as VRX ratio turned negative. 67 grew positions while 54 funds acquired positions. Funds hold 169.66 million shares thus 0.12% less from 2017Q3’s 169.87 million shares. Bridgecreek Invest Llc holds 1.77% or 362,275 shs in its capital. Stifel Corporation has 218,123 shs. Dekabank Deutsche Girozentrale invested in 87,000 shs or 0.01% of the stock. Brown Brothers Harriman & holds 0% or 30,000 shs. Vanguard Gp reported 8.01M shs. Iron Fincl Limited Liability Com owns 16,394 shs. New York-based Cohen Klingenstein Limited Liability Corporation has invested 0.05% in Valeant Pharmaceuticals International, Inc. (NYSE:VRX). Valueact LP owns 3.79% invested in Valeant Pharmaceuticals International, Inc. (NYSE:VRX) for 18.01 million shs. Montrusco Bolton Investments Inc invested 0.34% of its capital in Valeant Pharmaceuticals International, Inc. (NYSE:VRX). State Bank Of Ny Mellon Corporation reported 359,894 shs. Wells Fargo & Mn holds 0% or 271,299 shs. Pnc Fincl Services holds 0% or 10,839 shs in its capital. 4,000 were reported by Winslow Evans And Crocker Inc. 10,000 were accumulated by Keybank Natl Association Oh. Rbf Capital Lc holds 0.83% or 361,100 shs in its capital.

VRX registered $876,370 net activity with 3 buys and 0 insider sales since March 8, 2018. PAPA JOSEPH C bought $481,500 worth of Valeant Pharmaceuticals International, Inc. (NYSE:VRX) on Tuesday, March 13. On Tuesday, March 13 Herendeen Paul also bought $241,470 worth of Valeant Pharmaceuticals International, Inc. (NYSE:VRX).

In 2017Q4 Securities and Exchange filling is reported George Soros’s holdings in Valeant Pharmaceuticals Intl (Put) (VRX) which was decreased by 30.56%. The company’s stock sank 28.77% while Soros Fund Management Llc sold 660,000 shares. The hedge fund run by George Soros is holding 1.50 million shares, compared to the 2.16 million from the previous quarter. And the reported value of the health care company is $31.17M for the 2017Q4. $5.98 billion is Valeant Pharmaceuticals Intl (Put)’s market cap. VRX reached $17.15 on during the last trading session after $0.52 change.Valeant Pharmaceuticals International, Inc. has volume of 10.80M shares. Since April 14, 2017 VRX has risen 42.00% and is uptrending. The stock outperformed the S&P 500 by 30.45%.

About $4.37 billion US Long portfolio the Soros Fund Management Llc operates. According to a filing the fund upped its stake in Charter Communications Inc N by 24,300 shares to 49,300 shares, valued at $16.56M in 2017Q4. For a total of 250,100 shares it increased its holding in Eqt Corp (Call) (NYSE:EQT) by 170,100 shares in the quarter, and has risen its stake in Caesars Entmt Corp (NASDAQ:CZR).

Analysts await Valeant Pharmaceuticals International, Inc. (NYSE:VRX) to report earnings on May, 8. They expect $0.66 EPS, down 76.43 % or $2.14 from last year’s $2.8 per share. VRX’s profit will be $230.25M for 6.50 P/E if the $0.66 EPS becomes a reality. After $0.98 actual EPS reported by Valeant Pharmaceuticals International, Inc. for the previous quarter, Wall Street now forecasts -32.65 % negative EPS growth.

Valeant Pharmaceuticals International, Inc. (NYSE:VRX) Ratings Coverage

In total 15 analysts cover Valeant Pharma (NYSE:VRX). “Buy” rating has 3, “Sell” are 4, while 8 are “Hold”. 20% are bullish. With $25.0 highest and $7.0 lowest [Target] Valeant Pharma has $16.27 average [Target] or -5.13% below the current ($17.15) price. 30 are the (NYSE:VRX)’s analyst reports since October 16, 2017 according to StockzIntelligence Inc. On Friday, December 15 Mizuho maintained Valeant Pharmaceuticals International, Inc. (NYSE:VRX) rating. Mizuho has “Underperform” rating and $10 target. On Thursday, December 14 the company was downgraded by JP Morgan. On Wednesday, February 28 the rating was maintained by Cantor Fitzgerald with “Buy”. On Monday, February 26 the rating was maintained by Canaccord Genuity with “Hold”. On Tuesday, January 16 H.C. Wainwright maintained Valeant Pharmaceuticals International, Inc. (NYSE:VRX) with “Hold” rating. On Tuesday, November 7 the stock of Valeant Pharmaceuticals International, Inc. (NYSE:VRX) has “Buy” rating given by Cantor Fitzgerald. On Friday, November 3 the stock of Valeant Pharmaceuticals International, Inc. (NYSE:VRX) has “Hold” rating given by H.C. Wainwright. In Wednesday, February 28 report CFRA downgraded the stock to “Hold” rating. On Tuesday, November 7 the stock of Valeant Pharmaceuticals International, Inc. (NYSE:VRX) earned “Sell” rating by Mizuho. The stock rating was maintained by Piper Jaffray with “Sell” on Friday, October 20.

Valeant Pharmaceuticals International, Inc. (NYSE:VRX) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.